N-methyl, N-(6-(methoxy)pyridazin-3-yl)amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases

Abstract

To provide means for treating inflammatory airway or fibrotic diseases.SOLUTION: The present invention relates to N-methyl, N-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IPF) or systemic sclerosis (SSc). The present description discloses exemplary compounds (e.g. pages 57 to 75; examples 1.1 to 5) as well as relevant biological data thereof (e.g. pages 15 to 21, tables 1 to 9). An exemplary compound is e.g. 1-(6-(4-(((6-((6-(trifluoromethyl) pyridin-3-yl)methoxy)pyridazin-3-yl)amino)methyl)phenyl)-2,6- diazaspiro[3.3]heptan-2-yl)ethan-1-one (example 1.1).SELECTED DRAWING: None

Description

[Technical Field]

[0001] FIELD OF THE INVENTION The present invention relates to novel dapyridines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and / or prevention of diseases and disorders mediated by autotaxin. [Background technology]

[0002] Background of the Invention Autotaxin (ATX; ENPP2) is a secreted enzyme responsible for hydrolyzing lysophosphatidylcholine (LPC) to the bioactive lipid lysophosphatidic acid (LPA) via its lysophospholipase D activity. LPA then exerts its effects by interacting with six GPCRs (LPA receptors 1-6, LPAR1-6) (Houben AJ, 2011). ATX-LPA signaling has been implicated in, for example, angiogenesis, chronic inflammation, autoimmune diseases, fibrotic diseases, cancer progression, and tumor metastasis. For example, LPA acting on LPAR1 induces lung fibroblast migration, proliferation, and differentiation; regulates epithelial and endothelial barrier function; and promotes lung epithelial cell apoptosis (Budd, 2013). ATX inhibition, LPAR1 gene deletion, and selective LPAR1 antagonists have been shown to be effective in preclinical models of lung and skin fibrosis (Tager AM, 2008; Swaney J, 2010, Casetelino FV, 2016).

[0003] In patients with idiopathic pulmonary fibrosis (IPF), LPA levels are elevated in bronchoalveolar lavage fluid (Tager et al., 2008, Nat. Med.), elevated concentrations of ATX have been detected in human fibrotic lung tissue (Oikonomou et al., 2012, AJRCMB), LPA levels are elevated in exhaled breath condensate of IPF subjects (Montesi et al., 2014_BMCPM), and LPC is increased two-fold in the serum of patients with stable IPF (Rindlisbacher et al., 2018, Resp. Res.). Thus, elevated ATX and / or LPA levels, altered LPA receptor expression, and altered responses to LPA may influence many pathophysiological conditions implicated in ATX-LPA signaling.

[0004] Interstitial lung diseases (ILDs) are characterized by inflammation and fibrosis of the lung interstitium, the tissue and spaces between the air sacs (du Bois, Nat. Rev. Drug Discov. 2010, 9, 129-140). ILDs can arise when injury to the lung triggers an abnormal healing response. ILDs therefore include progressive fibrotic interstitial lung diseases (PFILDs), in which the response to lung injury becomes progressive and self-sustaining, independent of the initial clinical association or trigger. The most prominent PFILDs are idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-ILD ​​(SSc-ILD). IPF is a chronic, fibrotic, irreversible, and ultimately fatal lung disease characterized by progressive fibrosis in the pulmonary interstitium, which reduces lung volume and leads to progressive pulmonary dysfunction. IPF is also characterized by a distinctive histopathological pattern known as usual interstitial pneumonia (UIP) (Raghu et al., Am. J. Respir. Crit. Care Med. 183: 788-824).

[0005] Systemic sclerosis (SSc), also known as scleroderma, is an immune-mediated rheumatic disease with complex etiology. It is a multiorgan heterogeneous disease characterized by extensive fibrosis, vasculopathy, and autoantibodies against various cellular antigens, and is associated with a high mortality rate. It is a rare disorder, i.e., a debilitating disease with a significant unmet need. Early clinical signs of SSc can be diverse. Raynaud's phenomenon and gastroesophageal reflux are often present early in the disease (Rongioletti F, et al., J Eur Acad Dermatol Venereol 2015; 29: 2399-404). Some patients present with inflammatory skin disease, puffy, swollen fingers, musculoskeletal inflammation, or constitutional signs such as fatigue. Excessive collagen deposition in the skin of these patients causes the skin to thicken and toughen. Some patients also exhibit organ-based manifestations of the disease, such as pulmonary fibrosis, pulmonary arterial hypertension, renal failure, or gastrointestinal complications. Furthermore, one of the most common signs of immune involvement is the presence of abnormal levels of autoimmune antibodies (antinuclear antibodies or ANA) directed against the nuclei of one's own cells, which is seen in almost everyone with SSc (Guiducci S et al., Isr Med Assoc J 2016; 18: 141-43). ILD and pulmonary arterial hypertension (PAH) are the most frequent causes of death in SSc patients (Tyndall AJ et al. Ann Rheum Dis 2010; 69: 1809-15).

[0006] Patients with SSc are classified into two major disease subsets: diffuse cutaneous sclerosing systemic sclerosis and limited cutaneous sclerosing systemic sclerosis (LeRoy EC, et al., J Rheumatol 1988; 15:202-5). Three clinical features, namely, excessive fibrosis (scarring), vasculopathy, and autoimmunity, emerge and form the basis of the process that leads to the various symptoms that characterize SSc. SSc is currently considered a manifestation of dysregulated or dysfunctional repair of connective tissue following injury (Denton CP et al., Lancet 2017; 390: 1685-99). It is therefore desirable to provide potent ATX inhibitors.

[0007] Various structural classes of ATX inhibitors are reviewed in D. Castagna et al. (J.Med.Chem. 2016, 59, 5604-5621). WO2014 / 139882 discloses compounds that are ATX inhibitors having the following generalized structural formula: [ka]

[0008] Example 2 therein is further disclosed by N. Desroy, et al. (J.Med.Chem. 2017, 60, 3580-3590, as Example 11) as a first-in-class ATX inhibitor undergoing clinical evaluation for the treatment of idiopathic pulmonary fibrosis. C. Kuttruff, et al. (ACS Med. Chem. Lett. 2017, 8, 1252-1257) discloses an ATX inhibitor, BI-2545 (Example 19), which significantly reduces LPA levels in vivo. Summary of the Invention

[0009] Detailed Description of the Invention The present invention is surprisingly a potent inhibitor of autotaxin (Assay A) and further -High potency in human whole blood (Assay B), and - Significant reduction in plasma levels of LPA in vivo over several hours (Assay C) The present invention provides a novel pyridazine characterized by the following: The compounds of the present invention are useful as agents for the treatment or prevention of diseases or conditions in which ATX activity and / or LPA signaling are involved, and which are involved in the etiology or pathology of the disease or are otherwise associated with at least one symptom of the disease. ATX-LPA signaling has been implicated in, for example, angiogenesis, chronic inflammation, autoimmune diseases, fibrotic diseases, cancer progression, and tumor metastasis.

[0010] The compounds of the present invention exhibit the following parameters: - Efficacy as an ATX inhibitor, - Potency as an ATX inhibitor in human whole blood, -Reduces plasma levels of LPA in vivo over several hours The combination of ATX is a soluble plasma protein active in heparinized whole blood. Its substrate, LPC, is present in very high amounts, with concentrations in the μM range. Therefore, whole blood assays at physiological substrate concentrations are highly relevant for predicting the efficacy of ATX inhibitors in vivo.

[0011] In vivo LPA reduction is determined by measuring plasma LPA concentrations after oral administration of compounds of the present invention. LPA is a highly potent bioactive lipid, efficiently activating downstream pathways via LPA receptors 1-6 in a concentration-dependent manner. A pronounced and sustained blockade of LPA formation via ATX inhibition is assayed by measuring the extent of LPA reduction 8 hours after compound administration. Thus, the significant reduction in plasma LPA at 8 hours is highly indicative of not only the efficacy and duration of action in vivo, but also sustained target engagement of LPA receptors. The compounds of the present invention are structurally distinct from Examples 2 and 12 of WO2014 / 139882 and Example 19 of ACS Med. Chem. Lett. 2017, 8, 1252-1257, i.e., the compounds of the present invention contain a central pyridazine core with substituents at positions 3 and 6. This structural difference unexpectedly results in a superior combination of (i) inhibition of ATX, (ii) inhibition of ATX in human whole blood, and (iii) reduction of plasma levels of LPA in vivo over several hours. As a result, compounds of the present invention exhibit high in vivo target engagement and can be predicted to have greater efficacy in humans.

[0012] The present invention provides novel compounds of formula (I): [ka] (I) During the ceremony, A is fluoro and F 1-7 -Fluoro-C 1-3 -pyridyl substituted with one or two members of the group consisting of alkyl; E is fluoro and F is 1-7 -Fluoro-C 1-3 - selected from the group consisting of phenyl and pyridyl, optionally substituted with one or two members of the group consisting of alkyl;

[0013] K is the following group [ka] selected from the group consisting of: R 3 is R 4 (O)C-, oxetanyl, methyl, R 5 (O)C(CH3)N- and R 5 (O)CHN-; R 4 is methyl; R 5 is methyl.

[0014] Another embodiment of the present invention is where A is F, F 1-3 -pyridyl substituted with one or two members of the group consisting of -fluoro-C1-alkyl; and the substituents E and K are as defined in the preceding embodiments. Another embodiment of this invention relates to compounds of formula (I) wherein A is pyridyl substituted with one or two members of the group consisting of F, F2HC, and F3C; and the substituents E and K are as defined in the preceding embodiments.

[0015] Another embodiment of the present invention is where A is [ka] selected from the group consisting of: and the substituents E and K are as defined in any of the preceding embodiments. Another embodiment of the present invention is wherein E is selected from the group consisting of phenyl and pyridyl optionally substituted with one or two members of the group consisting of F, F2HC, and F3C; and the substituents A and K are as defined in any of the preceding embodiments. Another embodiment of the present invention is wherein E is selected from the group consisting of phenyl and pyridyl optionally substituted with one or two members of the group consisting of F and F3C; and the substituents A and K are as defined in any of the preceding embodiments.

[0016] Another embodiment of the present invention is where E is a group [ka] selected from the group consisting of: and the substituents A and K are as defined in any of the preceding embodiments.

[0017] According to the present invention, preferably the compound of formula (I) is selected from the group consisting of the following compounds: [ka]

[0018] [ka]

[0019] [ka]

[0020] [ka]

[0021] [ka]

[0022] A further embodiment relates to a pharmaceutical composition comprising at least one compound of formula I of the present invention or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. A further embodiment relates to a compound of formula (I) of the present invention for use as a medicament. DETAILED DESCRIPTION OF THE INVENTION

[0023] Terms and definitions used Terms not specifically defined herein shall be given the meaning that one of ordinary skill in the art would give them in light of this disclosure and the context. However, as used herein, unless otherwise specified, the following terms have the indicated meanings and adhere to the following conventions. In the groups, radicals, or moieties below, the number of carbon atoms is often specified prior to the group, e.g., C 1-6 -Alkyl refers to an alkyl group having 1 to 6 carbon atoms. In general, for groups such as HO, H2N, (O)S, (O)2S, NC (cyano), HOOC, F3C, etc., the point of attachment of the group to the molecule will be known to one skilled in the art from the free valence of the group itself. For combination groups containing two or more subgroups, the last-named subgroup is the point of attachment of the group; for example, the substituent "aryl-C 1-3 -Alkyl" is C 1-3 -means an aryl group bonded to an alkyl group, wherein the alkyl group is bonded to the core or group to which the substituent is attached. When the compounds of the invention are depicted in the form of chemical names and as chemical formulas, the formulas shall prevail in the event of any discrepancy. An asterisk may be used in sub-formulas to indicate a bond that is attached to the core molecule as defined. The numbering of the atoms of a substituent begins with the atom closest to the core or group to which the substituent is attached.

[0024] For example, the term "3-carboxypropyl group" represents the following substituent: [ka] wherein the carboxy group is attached to the third carbon atom of the propyl group. The term "1-methylpropyl-", "2,2-dimethylpropyl-" or "cyclopropylmethyl-" represents the following group: [ka]

[0025] An asterisk may be used in a sub-formula to represent a bond that is attached to the core molecule as defined. As used herein, the term "substituted" means that any one or more hydrogens on the designated atom have been replaced with a selection from the indicated group, provided that the normal valence of the designated atom is not exceeded and provided that the substitution results in a stable compound. The term "C" alone or in combination with other groups 1-n -alkyl" (n is an integer selected from 2, 3, 4, 5 or 6, preferably 4 or 6) means an acyclic saturated branched or straight chain hydrocarbon group having 1 to n C atoms. For example, the term C 1-5 -Alkyl is the group H3C-, H3C-CH2-, H3C-CH2-CH2-, H3C-CH(CH3)-, H3C-CH2-CH2-CH2-, H3C- CH2-CH(CH3)-, H3C-CH(CH3)-CH2-, H3C-C(CH3)2-, H3C-CH2-CH2-CH2-CH2-, H3C-C Includes H2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-CH2-, H3C-CH(CH3)-CH2-CH2-, H3C-CH2-C(CH3)2-, H3C-C(CH3)2-CH2-, H3C-CH(CH3)-CH(CH3)- and H3C-CH2-CH(CH2CH3)-. The term "halogen" refers to chlorine, bromine, iodine, and fluorine. The term "halo" attached to an "alkyl," "alkylene," or "cycloalkyl" group (saturated or unsaturated) refers to the alkyl or cycloalkyl group having one or more hydrogen atoms replaced by a halogen atom selected from fluorine, chlorine, or bromine, preferably fluorine and chlorine, and most preferably fluorine. Examples include HFC-, HFC-, and FC-.

[0026] The term phenyl refers to the following ring radical: [ka]

[0027] The term pyridinyl refers to the following ring radical: [ka]

[0028] The term pyridazine refers to the ring: [ka]

[0029] The term oxetanyl refers to the ring: [ka]

[0030] Unless otherwise specifically indicated, throughout this specification and the appended claims, a given chemical formula or chemical name is intended to encompass tautomers and all stereo, optical, and geometric isomers (e.g., enantiomers, diastereomers, E / Z isomers, etc.) and not only racemates thereof but also mixtures of different ratios of separate enantiomers, mixtures of diastereomers, or mixtures of any of the aforementioned forms in which said isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts, and solvates thereof, including, for example, solvates of the free compound or solvates of a salt of the compound. In general, substantially pure stereoisomers can be obtained according to synthetic principles known to those skilled in the art, for example, by separation of corresponding mixtures, by the use of stereochemically pure starting materials and / or by stereoselective synthesis. It is well known in the art how to prepare optically active forms, for example, by resolution of racemic forms or by synthesis starting from optically active starting materials and / or by the use of chiral reagents.

[0031] Enantiomerically pure compounds or intermediates of the present invention may be prepared via asymmetric synthesis, for example by preparative separation of suitable diastereomeric compounds or intermediates which can be separated by known methods (e.g., chromatographic separation or crystallization) and / or by using chiral reagents, such as chiral starting materials, chiral catalysts or chiral auxiliaries. Furthermore, those skilled in the art know how to prepare enantiomerically pure compounds from the corresponding racemic mixtures, such as, for example, by chromatographic separation of the corresponding racemic mixtures on chiral stationary phases; or by resolution of the racemic mixtures with suitable resolving agents, for example, by formation of diastereomeric salts of the racemates with optically active acids or bases, followed by separation of the salts and liberation of the desired compound from the salts; or by derivatization of the corresponding racemates with optically active chiral auxiliary reagents, followed by diastereomeric separation and removal of the chiral auxiliary; or by kinetic resolution (e.g., enzymatic resolution) of the racemates; by enantioselective crystallization under appropriate conditions from a conglomerate of mirror image crystals; or by (fractional) crystallization from a suitable solvent in the presence of an optically active chiral auxiliary.

[0032] The expression "pharmaceutically acceptable" is used herein to refer to those compounds, substances, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use without undue toxicity, irritation, allergic response, or other problem or complication and commensurate with a reasonable benefit / risk ratio. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds where the parent compound forms salts or complexes with acids or bases. Examples of acids that form pharmaceutically acceptable salts with the parent compound that contains a basic moiety include mineral or organic acids, such as benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid, and tartaric acid.

[0033] Examples of cations and bases that form pharmaceutically acceptable salts with the parent compound that contains an acidic moiety include Na + , K. + , Ca 2+ , Mg 2+ , NH4 + , L-arginine, 2,2'-iminobisethanol, L-lysine, N-methyl-D-glucamine, or tris(hydroxymethyl)-aminomethane. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains an acidic or basic moiety by conventional chemical methods. Generally, the salts can be prepared by reacting the free acid or base form of these compounds with a sufficient amount of the appropriate base or acid in water or a suitable organic diluent such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof. Salts of acids other than those mentioned above (eg, trifluoroacetates), which are useful, for example, for purifying or isolating the compounds of the invention, also form part of this invention.

[0034] Biological assays The biological activity of the compounds was determined by the following methods. Assay A: Biochemical ATX assay 50 mM Tris buffer (pH 8.0) containing 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.14 mM NaCl, and 0.1% bovine serum albumin was supplemented with 5 nM recombinant ATX (Cayman Chemicals). Test compounds were dissolved in DMSO and tested over a range of 0.1 nM to 10 μM. The enzyme reaction (22.5 μL) was initiated by the addition of 2.5 μL of 10 μM 18:1 LPC (Avanti Lipids, Alabaster, AL, USA). After 2 h of incubation at room temperature, the reaction was stopped by the addition of 20 μL of water containing 500 nM 20:4 LPA as an internal standard and 100 μL of 1-butanol to extract the LPA. The plate was then centrifuged at 4000 rpm for 2 min at 4°C. The resulting upper butanol phase was used directly for injection on a RapidFire system (Agilent).

[0035] A RapidFire autosampler was connected to a binary pump (Agilent 1290) and a Triple Quad 6500 (ABSciex, Toronto, Canada). The system was equipped with a 10 μL loop, a 5 μL Waters Atlantis HILIC cartridge (Waters, Elstree, UK), 90% acetonitrile containing 10 mM ammonium acetate as eluent A, and 40% acetonitrile containing 10 mM ammonium acetate as eluent B. See below for details (Bretschneider et al., SLAS Discovery, 2017). One MS was operated in negative mode with a source temperature of 550 °C, curtain gas = 35, gas 1 = 65, and gas 2 = 80. The following transition and MS parameters (DP: declustering potential and CE: collision energy) were determined for each LPA: 18:1 LPA 435.2 / 152.8, DP=-40, CE=-28 and 20:4 LPA 457.2 / 152.8, DP=-100, CE=-27). The formation of 18:1 LPA was monitored and assessed as a ratio to 20:4 LPA.

[0036] Table 1: Biological data of compounds of the invention obtained by Assay A [Table 1]

[0037] Table 2: Biological data of prior art compounds (Examples 2 and 12 of WO2014 / 139882) obtained in Assay A [Table 2]

[0038] Table 3: Biological data of prior art compounds (Example 19 of ACS Med. Chem. Lett. 2017, 8, 1252-1257) obtained in Assay A [Table 3]

[0039] Assay B: Whole blood ATX assay 5 μL of test compound (concentration range: 0.12 nM to 100 μM) dissolved in phosphate-buffered saline was supplemented with 45 μL of human whole blood. The mixture was incubated for 1 h at 37°C and stopped by adding 100 μL of 40 mM disodium hydrogen phosphate buffer containing 30 mM citric acid (pH 4) and 1 μM 17:0 LPA (internal standard). LPA was extracted by adding 500 μL of 1-butanol and then centrifuged at 4000 rpm for 10 min at 4°C. 200 μL aliquots of the resulting organic supernatant were transferred to a 96-deep-well plate for RapidFire-based MS / MS measurements. A RapidFire autosampler was connected to a binary pump (Agilent 1290) and a Triple Quad 6500 (ABSciex, Toronto, Canada). The system was equipped with a 10 μL loop, a 5 μL Waters Atlantis HILIC cartridge (Waters, Elstree, UK), 90% acetonitrile containing 10 mM ammonium acetate as eluent A, and 40% acetonitrile containing 10 mM ammonium acetate as eluent B. See below for details (Bretschneider et al., SLAS Discovery, 2017, 22, 425-432). The MS was operated in negative mode with a source temperature of 550 °C, curtain gas = 35, gas 1 = 65, and gas 2 = 80. The following transitions and MS parameters (DP: declustering potential and CE: collision energy) were determined for each LPA: 18:2 LPA 433.2 / 152.8, DP=-150, CE=-27 and 17:0 LPA 423.5 / 152.8, DP=-100. The formation of 18:2 LPA was monitored and assessed as a ratio to 17:0 LPA.

[0040] Table 4: Biological data of compounds of the invention obtained in Assay B [Table 4]

[0041] Table 5: Biological data of prior art compounds (Examples 2 and 12 of WO2014 / 139882) obtained in Assay B [Table 5]

[0042] Table 6: Biological data of the prior art compound (Example 19 of ACS Med. Chem. Lett. 2017, 8, 1252-1257) obtained in Assay B [Table 6]

[0043] Assay C: In vivo Test substances were solubilized in 0.5% natrosol supplemented with 0.015% Tween 80 for oral administration to rats at a dose of 5 mg / kg. Blood samples were collected before compound administration and 8 hours after administration on ice using EDTA as a coagulant. Plasma was subsequently prepared by centrifugation and stored at -20°C until analysis. LPA from plasma samples was extracted using the procedure described by Scherer et al. (Clinical Chemistry 2009, 55, 1218-22). 35 μL of heparinized plasma was mixed with 200 μL of 40 mM disodium hydrogen phosphate buffer containing 30 mM citric acid (pH 4) and 1 μM 17:0 LPA (internal standard). Subsequently, 500 μL of butanol was added and the mixture was vigorously shaken for 10 minutes. The samples were then centrifuged at 4000 rpm and 4°C for 10 minutes. 500 μL of the organic upper phase was transferred to a fresh 96-deep-well plate and centrifuged at 15 psi (1.03 × 10 5 The mixture was evaporated with a gentle stream of nitrogen at 1000 Pa for 45 min. The resulting residue was dissolved in 100 μL of ethanol before LC-MS analysis.

[0044] LC-MS methods for the analysis of in vivo samples A Triple Quad 6500 (ABSciex, Toronto, Canada) was equipped with an Agilent 1290 LC system (Agilent, Santa Clara, CA), a CTC autosampler, and an Atlantis 50 × 2.1 mm, 3 μm HILIC LC column (Waters, Elstree, UK). Eluent A contained 0.2% formic acid and 50 mM ammonium formate in water, while eluent B consisted of 0.2% formic acid in acetonitrile. The LC gradient started with 95% solvent B, reduced to 75% within 1.5 min and 50% within 0.2 min, and then further diluted from 500 to 700 μL min -1At 1.8 min, solvent B was returned to 95% and held constant for 0.7 min to re-equilibrate the column. The following LPA species were monitored (DP: declustering potential and CE: collision energy): 16:0 LPA 409.2 / 152.8, DP = -150, CE = -28; 18:0 LPA 437.3 / 152.8, DP = -60, CE = -28; 18:1 LPA 435.2 / 152.8, DP = -40, CE = -28; 18:2 LPA 433.2 / 152.8, DP = -150, CE = -28; 20:4 LPA 457.2 / 152.8, DP = -100, CE = -29, and 17:0 LPA 423.5 / 152.8, DP = -100, CE = -36. Percent LPA reduction was calculated based on baseline LPA levels before test compound application. Total LPA refers to the species 16:0; 18:0; 18:1; 18:2 and 20:4.

[0045] Table 7: Biological data of compounds of the invention obtained in Assay C [Table 7]

[0046] Table 8: Biological data of prior art compounds (Examples 2 and 12 of WO2014 / 139882) obtained in Assay C [Table 8]

[0047] Table 9: Biological data of the prior art compound (Example 19 of ACS Med. Chem. Lett. 2017, 8, 1252-1257) obtained in Assay C [Table 9]

[0048] Treatment method The present invention relates to compounds of general formula (I) that are useful for the prevention and / or treatment of diseases and / or conditions associated with or modulated by the physiological activity of ATX and / or LPA, such as, but not limited to, inflammatory conditions, fibrotic diseases, respiratory conditions, renal conditions, hepatic conditions, vascular and cardiovascular conditions, cancer, ophthalmic conditions, metabolic conditions, cholestatic and other forms of chronic pruritus, and acute and chronic organ transplant rejection and neurological conditions.

[0049] Compounds of general formula (I) are useful in treating inflammatory conditions such as, but not limited to, Sjogren's syndrome, arthritis, osteoarthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD) and chronic asthma; fibrotic diseases such as, but not limited to, interstitial lung diseases (ILDs) such as progressive fibrosing interstitial lung diseases (PFILDs) such as idiopathic pulmonary fibrosis (IPF) and SSC-ILD, familial interstitial lung disease, myocardial and vascular fibrosis, renal fibrosis, hepatic fibrosis, pulmonary fibrosis, skin fibrosis, collagen vascular diseases such as systemic sclerosis (SSc) and encapsulating peritonitis. respiratory conditions, including, but not limited to, diffuse parenchymal lung diseases of various etiologies, such as iatrogenic drug-induced fibrosis, occupational and / or environmental induced fibrosis, systemic diseases and vasculitis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), renal conditions, including, but not limited to, end-stage renal disease (ESRD), focal segmental glomerulosclerosis, IgA nephropathy, vasculitis / systemic disease, and acute kidney injury and chronic kidney disease (with and without proteinuria), including acute and chronic renal transplant rejection; hepatic conditions, including, but not limited to, cirrhosis, hepatic congestion, cholestatic liver disease, such as pruritus, primary biliary cholangitis, non-alcoholic steatohepatitis, and acute and chronic liver transplant rejection; vascular conditions, including, but not limited to, atherosclerotic arteriosclerosis, thrombotic vascular disease and thrombotic microangiopathy, proliferative arteriopathy (e.g., swollen myointimal cells and nodular thickening surrounded by a mucous extracellular matrix), endothelial dysfunction, etc.; cardiovascular conditions, such as, but not limited to, acute coronary syndromes, coronary heart disease, myocardial infarction, arterial pulmonary hypertension, arrhythmias such as atrial fibrillation, stroke, and other vascular injuries, etc.; cancer and cancer metastasis, such as, but not limited to, breast cancer, ovarian cancer, lung cancer, prostate cancer, mesothelioma, glioma, liver cancer, gastrointestinal cancer, and their progressive and metastatic aggressiveness, etc.; ophthalmic conditions, such as, but not limited to, proliferative and non-proliferative (diabetic) retinopathy, dry and wet age-related macular degeneration (AMD), macular edema, central arterial / venous occlusion, trauma, glaucoma, etc.; metabolic conditions, such as, but not limited to, obesity, dyslipidemia, and diabetes, etc.;Useful for the prevention and / or treatment of nervous system conditions, including, but not limited to, neuropathic pain, Alzheimer's disease, schizophrenia, neuroinflammation (e.g., astrogliosis), peripheral and / or autonomic (diabetic) neuropathy, etc.;

[0050] Thus, the present invention relates to compounds of general formula (I) for use as pharmaceuticals. Furthermore, the present invention relates to the use of compounds of general formula (I) for the treatment and / or prevention of diseases and / or conditions associated with or modulated by the physiological activity of ATX and / or LPA. Furthermore, the present invention relates to the use of compounds of general formula (I) for the treatment and / or prevention of diseases and / or conditions associated with or modulated by the physiological activity of ATX and / or LPA, such as, but not limited to, inflammatory conditions, fibrotic diseases, respiratory conditions, renal conditions, hepatic conditions, vascular and cardiovascular conditions, cancer, ophthalmic conditions, metabolic conditions, cholestatic and other forms of chronic pruritus, as well as acute and chronic organ transplant rejection and nervous system conditions.

[0051] Furthermore, the present invention provides a method for treating inflammatory conditions, including, but not limited to, Sjogren's syndrome, arthritis, osteoarthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD) and chronic asthma; fibrotic diseases, including, but not limited to, interstitial lung diseases (ILDs), such as progressive fibrosing interstitial lung diseases (PFILDs), e.g., idiopathic pulmonary fibrosis (IPF), and SSC-ILD, familial interstitial lung disease, myocardial and vascular fibrosis, renal fibrosis, hepatic fibrosis, pulmonary fibrosis, skin fibrosis, collagen vascular diseases such as systemic sclerosis (SSc) and encapsulating peritonitis. respiratory conditions, including, but not limited to, diffuse parenchymal lung diseases of various etiologies, such as iatrogenic drug-induced fibrosis, occupational and / or environmental induced fibrosis, systemic diseases and vasculitis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), renal conditions, including, but not limited to, end-stage renal disease (ESRD), focal segmental glomerulosclerosis, IgA nephropathy, vasculitis / systemic disease, and acute kidney injury and chronic kidney disease (with and without proteinuria), including acute and chronic renal transplant rejection; hepatic conditions, including, but not limited to, cirrhosis, hepatic congestion, cholestatic liver disease, such as pruritus, primary biliary cholangitis, non-alcoholic steatohepatitis, and acute and chronic liver transplant rejection; vascular conditions, including, but not limited to, atherosclerotic arteriosclerosis, thrombotic vascular disease and thrombotic microangiopathy, proliferative arteriopathy (e.g., swollen myointimal cells and nodular thickening surrounded by a mucous extracellular matrix), endothelial dysfunction, etc.; cardiovascular conditions, such as, but not limited to, acute coronary syndromes, coronary heart disease, myocardial infarction, arterial pulmonary hypertension, arrhythmias such as atrial fibrillation, stroke, and other vascular injuries, etc.; cancer and cancer metastasis, such as, but not limited to, breast cancer, ovarian cancer, lung cancer, prostate cancer, mesothelioma, glioma, liver cancer, gastrointestinal cancer, and their progressive and metastatic aggressiveness, etc.; ophthalmic conditions, such as, but not limited to, proliferative and non-proliferative (diabetic) retinopathy, dry and wet age-related macular degeneration (AMD), macular edema, central arterial / venous occlusion, trauma, glaucoma, etc.; metabolic conditions, such as, but not limited to, obesity, dyslipidemia, and diabetes, etc.;The present invention relates to the use of compounds of general formula (I) for the treatment and / or prevention of conditions of the nervous system, such as, but not limited to, neuropathic pain, Alzheimer's disease, schizophrenia, neuroinflammation (e.g., astrogliosis), peripheral and / or autonomic (diabetic) neuropathy, etc.;

[0052] In a further aspect, the present invention relates to compounds of general formula (I) for use in the treatment and / or prevention of the above-mentioned diseases and conditions. In a further aspect, the present invention relates to the use of compounds of general formula (I) for the preparation of a medicament for the treatment and / or prevention of the above-mentioned diseases and conditions. In a further aspect, the present invention relates to a method for the treatment or prevention of the above-mentioned diseases and conditions, which method comprises the administration to humans of an effective amount of a compound of general formula (I).

[0053] Pharmaceutical Composition Suitable formulations for administration of compounds of formula (I) will be apparent to those skilled in the art and include, for example, tablets, pills, capsules, suppositories, lotions, troches, liquids, syrups, elixirs, sachets, injectables, inhalants and powders. Suitable tablets can be obtained, for example, by mixing one or more compounds of formula I with known excipients, such as inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and / or lubricants.

[0054] Combination therapy The compound of the present invention can be used in combination with other treatment options known in the art, so as to simultaneously treat the indications for which the present invention is useful, using at least two active compounds in effective amounts.Combined therapy preferably includes administering two active compounds to patients simultaneously, but the compounds do not need to be administered to patients simultaneously, although effective amounts of each compound will be present in patients at the same time.The compound of the present invention can be administered with one or more combination partners as described elsewhere herein. Thus, the present invention provides a compound of formula (I) according to any of the preceding embodiments, characterized in that the compound of formula (I) is administered in addition to treatment with one or more anti-inflammatory molecules from the list consisting of IL6 modulators, anti-IL6R modulators and IL13 / IL-4 JAKi modulators.

[0055] According to another aspect, the invention provides a compound of formula (I) according to any of the preceding embodiments, characterized in that the compound of formula (I) is administered in addition to treatment with one or more anti-fibrotic molecules from the list consisting of CB2 agonists, TGF modulators, FGFR modulators, VEGFR inhibitors, PDGFR inhibitors, FGF modulators, αvβ6 integrin modulators, anti-CTGF antibodies, ROCK2 inhibitors, rhPTX-2 (pentraxin-2), JNK1 inhibitors, LOXL2 inhibitors, galectin 3 inhibitors, MK2 inhibitors, Wnt pathway inhibitors, TGFR inhibitors, PDE4 modulators, TRPA1 inhibitors and microRNA modulators. According to another aspect, the invention provides a compound of formula (I) according to any of the preceding embodiments, wherein the compound of formula (I) is administered in addition to nintedanib. According to another aspect, the invention provides a compound of formula (I) according to any of the preceding embodiments, wherein the compound of formula (I) is administered in addition to pirfenidone.

[0056] preparation The compounds of the present invention can be obtained using synthetic methods known to those skilled in the art and described in the organic synthesis literature, and are preferably obtained similarly to the preparation methods described more fully below, particularly as described in the experimental section. The general process for preparing the compounds of the present invention will be apparent to those skilled in the art upon studying the following schemes. The starting materials may be prepared by methods described in the literature or herein, or prepared in an analogous or similar manner. Any functional group in the starting materials or intermediates may be protected using conventional protecting groups. These protecting groups may be cleaved again at an appropriate stage in the reaction sequence using methods familiar to those skilled in the art. [ka]

[0057] Compounds of general formula (I) can be prepared by the palladium-mediated Buchwald reaction or the copper-mediated Ullmann reaction of pyridazinyl halides or triflates (II) with amines (III), where X is a leaving group representing, for example, Cl, Br, I or OTf (triflate). [ka] Alternatively, compounds of general formula (I) can be prepared by the palladium-mediated Buchwald reaction or the copper-mediated Ullmann reaction of a pyridazinyl halide or triflate (VIII) with an alcohol (VII), where X is a leaving group representing, for example, Cl, Br, I or OTf (triflate). [Example]

[0058] Experimental Part The following examples are intended to illustrate the invention without limiting it: The terms "ambient temperature" and "room temperature" are used interchangeably to designate a temperature of about 20°C.

[0059] Abbreviation: [Table 10] JPEG0007797590000029.jpg228168 JPEG0007797590000030.jpg90164

[0060] Preparation of starting compounds Example I Example I.1 3-{[6-(difluoromethyl)pyridin-3-yl]methoxy}-6-iodopyridazine [ka]

[0061] 17.70 g (53.33 mmol) of 3,6-diiodopyridazine (CAS No. 20698-04-8) and 8.50 g (53.41 mmol) of [6-(difluoromethyl)pyridin-3-yl]methanol (CAS No. 946578-33-2) in 25 mL of THF are cooled to 0 °C, and 2.33 g (53.33 mmol) of sodium hydride (55% purity) are added. The reaction mixture is stirred overnight at RT and concentrated under reduced pressure. The residue is diluted with water (400 mL). The precipitate is filtered, washed with water and tBME, and dried overnight in vacuo at 50 °C to give 17.50 g of product. C 11 H8F2IN3O (M=363.1 g / mol) ESI-MS: 364 [M+H] + R t (HPLC): 0.90 min (Method A)

[0062] The following compounds are prepared according to the general procedure described above (Example I.1): [ka]

[0063] Example II Example II.1 4-(4-acetylpiperazin-1-yl)-3-fluorobenzonitrile [ka]

[0064] To a solution of 0.40 g (1.95 mmol) of 3-fluoro-4-piperazin-1-yl-benzonitrile (CAS No. 182181-38-0) and 0.60 mL (4.30 mmol) of triethylamine in 7 mL of DCM, add 0.14 mL (1.95 mmol) of acetyl chloride and stir the mixture at RT overnight. The reaction mixture is treated with 0.09 mL (1.25 mmol) of triethylamine and stirred at RT for 2 h. The organic layer is washed with water, dried over PTK, and the solvent is evaporated under reduced pressure to give 0.5 g of crude product, which is used in the next step without further purification. C 13 H 14 FNO (M = 247.3 g / mol) ESI-MS: 248 [M+H] + R t (HPLC): 0.82 B)

[0065] The following compounds are prepared according to the general procedure above (Example II.1): [ka]

[0066] Example III Example III.1 1-{4-[4-(aminomethyl)-2-fluorophenyl]piperazin-1-yl}ethan-1-one [ka]

[0067] A mixture of 550 mg (2.22 mmol) of 4-(4-acetylpiperazin-1-yl)-3-fluorobenzonitrile (Example II.1), 55.0 mg of Raney nickel, and 15 mL of 7N ammonia in MeOH was heated under a hydrogen atmosphere (50 psi (3.4 × 10 5 Stir overnight at 50°C under reduced pressure, filter and reduce in vacuo to give 0.51 g of product. C 13 H 18 FNO (M = 251.3 g / mol) ESI-MS: 252 [M+H] + R t (HPLC): 0.68 min (Method A)

[0068] The following compounds are prepared according to the general procedure above (Example III.1): [ka] JPEG0007797590000037.jpg236165 JPEG0007797590000038.jpg49161

[0069] Example IV Example IV.1 4-(4-acetylpiperazin-1-yl)-2-fluorobenzonitrile [ka]

[0070] A mixture of 0.50 g (2.50 mmol) of 4-bromo-2-fluorobenzonitrile (CAS No. 105942-08-3), 0.32 g (2.50 mmol) of 1-(piperazin-1-yl)ethan-1-one (CAS No. 13889-98-0), 1.63 g (5.00 mmol) of cesium carbonate, and 0.05 g (0.06 mmol) of XPhos Pd G3 (CAS No. 1445085-55-1) in 2 mL of 1,4-dioxane is stirred at 80 °C overnight. It is diluted with water. The remaining solid is filtered, washed with water, and dried under air to give 0.57 g of product. C 13 H 14 FNO (M = 247.3 g / mol) ESI-MS: 248 [M+H] + R t (HPLC): 0.79 min (Method A)

[0071] The following compounds are prepared according to the general procedure above (Example IV.1): [ka]

[0072] Example V Example V.1 4-{6-methyl-7-oxo-2,6-diazaspiro[3.4]octan-2-yl}benzonitrile [ka]

[0073] 222 mg (1.81 mmol) of 4-fluorobenzonitrile (CAS No. 1194-02-1) and 320 mg (1.81 mmol) of 6-methyl-2,6-diazaspiro[3.4]octan-7-one hydrochloride (CAS No. 2097951-61-4) diluted with 1.6 mL of DMSO are treated with 790 mg (5.62 mmol) of K2CO3 and stirred at 120 °C for 3 h and at RT overnight. The reaction mixture is cooled and diluted with water. The precipitate is filtered, washed with water, and dried in vacuo at 50 °C to give 340 mg of product. C 14 H 15 NO (M = 241.3 g / mol) ESI-MS: 242 [M+H] + R t (HPLC): 0.79 min (Method B)

[0074] The following compounds are prepared according to the general procedure above (Example V.1): [ka] JPEG0007797590000043.jpg208144 JPEG0007797590000044.jpg218146

[0075] [Table 11]

[0076] Example VI Example VI.1 4-{2,7-diazaspiro[3.5]nonan-2-yl}benzonitrile; Trifluoroacetic acid [ka]

[0077] 255 mg (0.78 mmol) of tert-butyl 2-(4-cyanophenyl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (Example V.2) are diluted with 5 mL of DCM and 300 μL (3.89 mmol) of TFA are added. The reaction mixture is stirred at RT for 2 h and concentrated under reduced pressure to give 0.26 g of product. C 14 H 17 N3 * C2HF3O2 (M = 341.3 g / mol) ESI-MS: 228 [M+H] + R t (HPLC): 0.69 min (Method B)

[0078] The following compounds are prepared according to the general procedure above (Example VI.1): [ka] JPEG0007797590000048.jpg87162

[0079] Example VII Example VII.1 4-{2,6-diazaspiro[3.3]heptan-2-yl}benzonitrile [ka]

[0080] A solution of 0.90 g (3.01 mmol) of tert-butyl 6-(4-cyanophenyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (Example V.3) in 8 mL of ACN is treated with 1.14 g (6.01 mmol) of p-toluenesulfonic acid monohydrate and stirred at RT for 24 h. The reaction mixture is diluted with DCM and extracted with saturated NaHCO3 solution. The combined organic layers are dried over MgSO4 and concentrated under reduced pressure to give 0.6 g of product. C 12 H 13 N3 (M = 199.3 g / mol) ESI-MS: 200 [M+H] + R t (HPLC): 0.62 min (Method B)

[0081] The following compounds are prepared according to the general procedure above (Example VII.1): [ka]

[0082] Example VIII N-[(4-bromophenyl)methyl]-6-{[6-(trifluoromethyl)pyridin-3-yl]methoxy}pyridazin-3-amine [ka]

[0083] 1000 mg (2.62 mmol) of 3-iodo-6-{[6-(trifluoromethyl)pyridin-3-yl]methoxy}pyridazine (Example I.2), 586 mg (3.15 mmol) of 4-bromobenzylamine, 50 mg (0.26 mmol) of copper iodide, 88 mg (0.52 mmol) of 2-(2-methyl-1-oxopropyl)cyclohexanone and 2.56 g (7.87 mmol) of cesium carbonate in 10 mL of DMF are stirred overnight at 60° C. The reaction mixture is purified by HPLC to give 850 mg of product. C 18 H 14 BrFNO (M = 439.2 g / mol) ESI-MS: 439 / 441 [M+H] + R t (HPLC): 1.08 min (Method A)

[0084] Example IX Example IX.1 5-(4-acetylpiperazin-1-yl)pyridine-2-carbonitrile [ka]

[0085] A mixture of 250 mg (2.05 mmol) of 5-fluoropyridine-2-carbonitrile (CAS No. 327056-62-2), 310 mg (2.46 mmol) of 1-acetylpiperazine (CAS No. 13889-98-0), and 700 μL (4.10 mmol) of DIPEA in 3 mL of DMSO is stirred at 80 °C for 45 min and quenched with semiconcentrated NaCl / solution. The aqueous phase is extracted with EtOAc. The combined organic phases are dried by PTK and concentrated in vacuo to give 0.57 g of product. C 12 H 14 NO (M = 230.3 g / mol) ESI-MS: 231 [M+H] + R t (HPLC): 0.67 min (Method A)

[0086] The following compounds are prepared according to the general procedure above (Example IX.1): [ka]

[0087] Example X Example X.1 4-(4-acetyl-3,3-dimethylpiperazin-1-yl)benzonitrile [ka]

[0088] 800 mg (1.21 mmol) of 4-(3,3-dimethylpiperazin-1-yl)benzonitrile trifluoroacetic acid (Example VI.3) are dissolved in 3 mL of pyridine and 2.00 mL (21.2 mmol) of acetic anhydride are added. The reaction mixture is refluxed overnight and evaporated under reduced pressure. The residue is taken up in saturated NaHCO3 solution and extracted with EtOAc. The organic layer is dried, concentrated in vacuo and purified by column chromatography (silica gel; gradient: DCM / MeOH = 98:2 → 9:1) to give the product. C 15 H 19 NO (M = 257.3 g / mol) ESI-MS: 258 [M+H] + R t (HPLC): 0.85 min (Method A)

[0089] The following compounds are prepared according to the general procedure above (Example X.1): [ka] JPEG0007797590000056.jpg116166

[0090] Example XI 6-(Difluoromethyl)-5-fluoropyridine-3-carboxylate methyl ester [ka]

[0091] 800 mg (3.54 mmol) of 5-bromo-2-(difluoromethyl)-3-fluoropyridine [prepared from commercially available 5-bromo-3-fluoropyridine-2-carboxaldehyde (1 equivalent), CAS-Nr. 669066-93-7, via overnight reaction with deoxofluor (2 equivalents) in DCM] in 40 mL of MeOH was treated with 154.8 mg (0.28 mmol) of 1,1'-bis-(diphenylphosphino)-ferrocene, 63.5 mg (0.28 mmol) of palladium(II) acetate, and 1.5 mL (10.79 mmol) of triethyl ether. The reaction mixture was stirred at 50 °C under a carbon monoxide atmosphere (5 bar) for 15 hours. The reaction mixture was filtered, and the filtrate was evaporated in vacuo to give the product. The residue is purified by column chromatography (silica gel; gradient: Cy / EE=100:0→60:40) to give 460 mg of product. C8H6F3NO2 (M = 205.1 g / mol) ESI-MS: 206 [M+H] + R t (HPLC): 0.88 min (Method B)

[0092] Example XII [6-(difluoromethyl)-5-fluoropyridin-3-yl]methanol [ka]

[0093] 98 mg (4.49 mmol) of lithium borohydride in 10 mL of THF is treated under a nitrogen atmosphere with 460 mg (2.42 mmol) of methyl 6-(difluoromethyl)-5-fluoropyridine-3-carboxylate (Example XI) dissolved in 10 mL of THF. 0.2 mL of MeOH is added and the reaction mixture is stirred at 50 °C for 2 h. The reaction mixture is diluted with 5 mL of 1 M hydrochloric acid and, after gas evolution, the THF is evaporated. The residue is made basic with 4 M NaOH and the aqueous solution is extracted with DCM. The organic phase is evaporated in vacuo to give the product. The residue is purified by column chromatography (silica gel; gradient: Cy / EE = 80:20 → 20:80) to give 290 mg of product. C7H6F3NO (M=177.1 g / mol) ESI-MS: 178 [M+H] + R t (HPLC): 0.64 min (Method B)

[0094] Example XIII 1-[(3aR,8aS)-Decahydropyrrolo[3,4-d]azepin-6-yl]ethan-1-one hydrochloride [ka]

[0095] 2.64 g (9.3 mmol) of tert-butyl (3aR,8aS)-6-acetyl-decahydropyrrolo[3,4-d]azepine-2-carboxylate (Example X.2) are diluted with 30 mL of 1,4-dioxane, 9.3 mL (37.4 mmol) of 4 M hydrogen chloride in 1,4-dioxane are added, and the reaction mixture is stirred at RT for 4 h. 1 equivalent of 4 M hydrogen chloride in 1,4-dioxane is added to the reaction mixture, which is stirred at RT overnight. The mixture is evaporated in vacuo, the residue is treated with diethyl ether, and the precipitate is filtered. The filter cake is diluted with MeOH and evaporated to give the product. C 10 H 18 N2O * HCl (M=182.3 g / mol) ESI-MS: 183 [M+H] + R t (HPLC): 0.50 min (Method A)

[0096] Example XIV N-(4-((3aR,3bS,6aR,6bS)-octahydrocyclobuta[1,2-c:3,4-c']dipyrrol-2(1H)-yl)benzyl)-6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-amine [ka]

[0097] Dissolve 59.7 mg (0.27 mmol) of (3aR,3bR,6aS,6bS)-decahydrocyclobuta[1,2-c:3,4-c']dipyrrole, 120.0 mg (0.27 mmol) of N-[(4-bromophenyl)methyl]-6-{[6-(trifluoromethyl)pyridin-3-yl]methoxy}pyridazin-3-amine (Example VIII), 3.07 mg (0.01 mmol) of palladium(II) acetate, 6.5 mg (0.01 mmol) of X-phos, and 89.0 mg (0.27 mmol) of cesium carbonate in 2.00 mL of toluene and 0.50 mL of tert-butanol under an argon atmosphere. Degas the solution several times. Stir the reaction mixture at 80 °C overnight. Dilute the reaction mixture with water and extract with EE. The organic layer is dried over MgSO4, filtered through charcoal and evaporated. The residue is purified by HPLC to give 15 mg of product. C 28 H 31 F3N6O2 (M = 496.5 g / mol) ESI-MS: 497 [M+H] + R t (HPLC): 0.98 min (Method A)

[0098] Preparation of final compounds Example 1.1 1-(6-(4-(((6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-yl)amino)methyl)phenyl)-2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one [ka]

[0099] To a solution of 163 mg (0.43 mmol) of 3-iodo-6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazine (Example I.2) and 150 mg (0.43 mmol) of 1-(6-(4-(aminomethyl)phenyl)-2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one (Example III.6) in 2 mL of dimethylacetamide, 418 mg (1.28 mmol) of cesium carbonate, 8.1 mg (0.04 mmol) of copper(I) iodide and 14.4 mg (0.09 mmol) of 2-(2-methyl-1-oxopropyl)cyclohexanone are added and the mixture is stirred overnight at 50 ° C. The mixture is diluted with acetonitrile, filtered and the filtrate is purified by HPLC to give 43 mg of the desired product. C 25 H 25 F3N6O2 (M = 498.5 g / mol) ESI-MS: 499 [M+H] + R t (HPLC): 0.93 min (Method A) 1 H NMR (400 MHz, DMSO-d6) δ 8.84 (d, J=1.52 Hz, 1H), 8.13 (dd, J=1.39, 8.11 Hz, 1H), 7.92 (d, J=8.11 Hz, 1H), 7.16 (d, J=8.49 Hz, 2H), 6.89-7.03 (m, 2H), 6.84 (t, J=5.64 Hz, 1H), 6.40 (d, J=8.49 Hz, 2H), 5.48 (s, 2H), 4.33 (d, J=5.58 Hz, 2H), 4.27 (s, 2H), 3.99 (s, 2H), 3.89 (s, 4H), 1.74 (s, 3H)

[0100] The following compounds are prepared according to the general procedure above (Example 1.1): [ka]

[0101] [Table 12]

[0102] [Table 13]

[0103] Example 2.1 N-Methyl-N-[1-(4-{[(6-{[6-(trifluoromethyl)pyridin-3-yl]methoxy}pyridazin-3-yl)amino]methyl}phenyl)piperidin-4-yl]acetamide [ka]

[0104] A mixture of 50.0 mg (0.13 mmol) of 3-iodo-6-{[6-(trifluoromethyl)pyridin-3-yl]methoxy}-pyridazine (Example I.2), 45.20 mg (0.14 mmol) of 1-{4-[4-(1-aminocyclopropyl)phenyl]-piperazin-1-yl}ethan-1-one (Example III.7), 6.2 mg (32.8 μmol) of copper iodide, 13.2 mg (0.07 mmol) of [(2,6-difluorophenyl)carbamoyl]formic acid (CAS No. 1018295-42-5), and 85.5 mg (0.39 mmol) of potassium phosphate in 2 mL of DMSO is stirred for 1.5 h at 80° C. and then for 1 h at 100° C. The reaction mixture is directly purified by HPLC to give 54 mg of product. C 26 H 29 F3N6O2 (M = 514.5 g / mol) ESI-MS: 515 [M+H]+ R t (HPLC): 0.60 min (Method C) 1 H NMR (400 MHz, DMSO-d6) δ 8.84 (d, J=1.14 Hz, 1H), 8.14 (dd, J=1.39, 8.11 Hz, 1H), 7.92 (d, J=8.11 Hz, 1H), 7.19 (d, J=8.24 Hz, 2H), 6.84-7.05 (m, 5H), 5.49 (s, 2H), 4.29-4.46 (m, 3H), 3.64-3.82 (m, 3H), 2.59-2.87 (m, 5H), 1.94-2.11 (m, 3H), 1.45-1.92 (m, 4H)

[0105] The following compounds are prepared according to the general procedure above (Example 2.1): [ka] JPEG0007797590000067.jpg211160 JPEG0007797590000068.jpg104156

[0106] [Table 14] JPEG0007797590000070.jpg63165

[0107] [Table 15] JPEG0007797590000072.jpg223162 JPEG0007797590000073.jpg145156

[0108] Example 3 1-[4-(4-{[(6-{[6-(difluoromethyl)pyridin-3-yl]methoxy}pyridazin-3-yl)amino]methyl}-phenyl)piperazin-1-yl]ethan-1-one [ka]

[0109] A mixture of 80.0 mg (0.22 mmol) of 3-{[6-(difluoromethyl)pyridin-3-yl]methoxy}-6-iodo-pyridazine (Example I.1), 61.7 mg (0.26 mmol) of 1-{4-[4-(aminomethyl)phenyl]piperazin-1-yl}ethan-1-one (Example III.5), 260 μL (0.66 mmol) of sodium tert-pentoxide (2.5 mol / L in methyl-THF) and 2.0 mg (2.20 μmol) of JOSIPHOS SL-J009-1 Pd G3 (MDL No. MFCD27978424) in 0.4 mL of tert-amyl alcohol is stirred overnight at 35 ° C. The reaction mixture is diluted with ACN and DMF, filtered and purified by preparative HPLC to give 12 mg of product. C 24 H 26 F2N6O2 (M = 468.5 g / mol) ESI-MS: 469 [M+H] + R t (HPLC): 0.88 min (Method A) 1 H NMR (400 MHz, DMSO-d6) δ 8.76 (d, J=1.39 Hz, 1H), 8.05 (dd, J=1.90, 7.98 Hz, 1H), 7.71 (d, J=7.98 Hz, 1H), 7.22 (d, J=8.62 Hz, 2H), 6.97-7.12 (m, 1H), 6.83-6.97 (m, 5H), 5.44 (s, 2H), 4.37 (d, J=5.58 Hz, 2H), 3.50-3.60 (m, 4H), 3.00-3.20 (m, 4H), 2.03 (s, 3H)

[0110] Example 4 1-[(3aR,8aS)-2-(4-{[(6-{[6-(trifluoromethyl)pyridin-3-yl]methoxy}pyridazin-3-yl)amino]methyl}phenyl)-decahydropyrrolo[3,4-d]azepin-6-yl]ethan-1-one [ka]

[0111] 59.7 mg (0.27 mmol) of 1-[(3aR,8aS)-decahydropyrrolo[3,4-d]azepin-6-yl]ethan-1-one hydrochloride (Example XIII), 100.0 mg (0.23 mmol) of N-[(4-bromophenyl)methyl]-6-{[6-(trifluoromethyl)pyridin-3-yl]methoxy}pyridazin-3-amine (Example VIII), 17.7 mg (0.02 mmol) of second-generation RuPhos precatalyst (2 nd Generation Ruphos precatalyst and 48.1 mg (0.50 mmol) of sodium tert-butoxide are dissolved in 1.00 mL of methyl-THF under an argon atmosphere. The solution is degassed several times. The reaction solution is stirred at 80 °C for 2 hours. Another 481 mg (0.50 mmol) of sodium tert-butoxide is then added and the reaction solution is stirred at 100 °C overnight. The reaction solution is filtered and purified by HPLC to give 14 mg of product. C 28 H 31 F3N6O2 (M = 540.6 g / mol) ESI-MS: 541 [M+H] + R t (HPLC): 0.81 min (Method F) 1H NMR (400 MHz, DMSO-d6) δ 8.84 (d, J=1.27 Hz, 1H), 8.13 (dd, J=1.46, 8.05 Hz, 1H), 7.92 (d, J=7.98 Hz, 1H), 7.14 (d, J=8.49 Hz, 2H), 6.90-7.05 (m, 2H), 6.79 (t, J=5.64 Hz, 1H), 6.47 (d, J=8.62 Hz, 2H), 5.49 (s, 2H), 4.31 (d, J=5.58 Hz, 2H), 3.57-3.80 (m, 2H), 3.33-3.46 (m, 4H), 3.20-3.30 (m, 2H), 2.93 (td, J=6.23, 9.35 Hz, 2H), 2.00 (s, 3H), 1.53-1.89 (m, 4H)

[0112] Example 5 1-((3aR,3bS,6aR,6bS)-5-(4-(((6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-yl)amino)methyl)phenyl)octahydrocyclobuta[1,2-c:3,4-c']dipyrrol-2(1H)-yl)ethan-1-one [ka]

[0113] 15 mg (0.03 mmol) of N-(4-((3aR,3bS,6aR,6bS)-octahydrocyclobuta[1,2-c:3,4-c']dipyrrol-2(1H)-yl)benzyl)-6-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-amine (Example XIV) is dissolved in 0.5 mL of DCM and 2.86 μL mL (0.03 mmol) of acetic anhydride is added. The reaction mixture is stirred for 1 h at RT. The reaction solution is diluted with 0.5 mL of MeOH and purified by HPLC to give 7 mg of product. C 28 H 29 F3N6O2 (M = 538.564 g / mol) ESI-MS: 539 [M+H] + R t (HPLC): 0.99 points (Method A) 1 H NMR (400 MHz, DMSO-d6) δ 9.12 (s, 1H), 8.89 (d, J=1.14 Hz, 1H), 8.19 (dd, J=1.52, 8.11 Hz, 1H), 7.94 (d, J=8.24 Hz, 1H), 7.85 (d, J=9.50 Hz, 1H), 7.41 (d, J=9.38 Hz, 1H), 7.08 (d, J=8.49 Hz, 2H), 6.65 (d, J=8.62 Hz, 2H), 5.63 (s, 2H), 5.06 (s, 2H), 3.79 (d, J=12.17 Hz, 1H), 3.66 (d, J=11.15 Hz, 1H), 3.54 (dd, J=1.90, 9.89 Hz, 2H), 3.35 (br dd, J=6.78, 11.22 Hz, 2H), 3.06 (dd, J=6.84, 12.29 Hz, 1H), 2.82 (br dd, J=6.97, 9.51 Hz, 2H), 2.55-2.64 (m, 1H), 2.44-2.49 (m, 2H), 2.02-2.06 (m, 3H)

[0114] Analytical HPLC Method A JPEG0007797590000077.jpg43161 analysis カラム: XBridge C18 (Waters) 2.5μm; 3.0×30mm; カラム temperature: 60℃ Method B JPEG0007797590000078.jpg42161 Analysis カラム:Stable Bond (Agilent) 1.8μm; 3.0×30mm; カラム temperature: 60℃ Method C JPEG0007797590000079.jpg38161 analysis カラム:XBridge (Waters) C18_3.0×30mm_2.5μm; カラム temperature: 60℃ Method D JPEG0007797590000080.jpg37162Analytical column: XBridge C18_3.0×30mm_2.5μm (Waters); column temperature: 60℃ Method E JPEG0007797590000081.jpg43161Analytical column: Sunfire (Waters) 2.5 μm; 3.0 × 30 mm; column temperature: 60 °C Method F JPEG0007797590000082.jpg38161Analytical column: XBridge C18 (Waters) 2.5 μm; 3.0 × 30 mm; column temperature: 60 °C Another aspect of the present invention may be as follows. [1] Below formula (I) [ka] (I) (In the formula, A is fluoro and F 1-7 -Fluoro-C 1-3 -pyridyl substituted with one or two members of the group consisting of alkyl; E is fluoro and F is 1-7 -Fluoro-C 1-3 - selected from the group consisting of phenyl and pyridyl, optionally substituted with one or two members of the group consisting of alkyl; K is the following group [ka] selected from the group consisting of: R 3 is R 4 (O)C-, oxetanyl, methyl, R 5 (O)C(CH 3 )N- and R 5 (O)CHN-; R 4 is methyl; R 5 is methyl) Compound. [2] A is F, F 1-3 -Fluoro-C 1 The compound of formula (I) according to [1] above, which is pyridyl substituted with one or two members of the group consisting of -alkyl. [3] A is the following group

change

change

change

change

change

change

change

[10] The compound according to any one of [1] to [8] above, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of idiopathic pulmonary fibrosis (IPF) or systemic sclerosis (SSc).

Claims

1. The following formula (I) 【Chemistry 1】 (I) (In the formula, A is pyridyl substituted with one or two members of the group consisting of fluoro and F 1-7 -fluoro-C 1-3 -alkyl; E is selected from the group consisting of phenyl and pyridyl optionally substituted with one or two members of the group consisting of fluoro and F 1-7 -fluoro-C 1-3 -alkyl; K is the following group 【Chemistry 2】 selected from the group consisting of: R3 is selected from the group consisting of R4(O)C-, oxetanyl, methyl, R5(O)C(CH3)N-, and R5(O)CHN-; R4 is methyl; R 5 is methyl) 1. A method for preparing a compound of formula (I), comprising: Below formula (III) 【change】 (wherein K and E have the same meanings as defined above) and a compound of the following formula (II): 【change】 (wherein A has the same meaning as above, X is a leaving group. with a compound of formula (I).

2. The method of claim 1, wherein A is pyridyl substituted with one or two members of the group consisting of F, F 1-3 -fluoro-C 1 -alkyl.

3. A is the following group 【Transformation 3】 2. The method of claim 1, wherein the compound is selected from the group consisting of:

4. The method of any one of claims 1 to 3, wherein E is selected from the group consisting of phenyl and pyridyl optionally substituted with one or two members of the group consisting of F, F2HC, and F3C.

5. E is the following group 【Chemistry 4】 The method of any one of claims 1 to 3, wherein the compound is selected from the group consisting of:

6. The compound of formula (I) is the following compound: 【Transformation 5】 【Transformation 6】 【Transformation 7】 【Transformation 8】 【Chemistry 9】 2. The method of claim 1, wherein the compound is selected from the group consisting of:

7. The method of claim 1, wherein X represents Cl, Br, I, or OTf (triflate).

Images